Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0876 • ACR Convergence 2020
Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials
Marina Magrey¹, Kurt de Vlam², Rebecca Bolce³, Soyi Liu-Leage⁴, Danting Zhu⁴, Theresa Hunter³, David Sandoval³ and Irene van der Horst-Bruinsma⁵, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ³Eli Lilly and Company, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to placebo in the treatment of patients with axial spondyloarthritis (axSpA) (Dougados M et…
Abstract Number: 1315 • ACR Convergence 2020
Exploring the Prevalence and Factors Associated with Fatigue in Axial Spondyloarthritis in a Multiethnic Asian Cohort in Singapore
Wei Ze Lim¹, Warren Fong², Yu Heng Kwan³ and Ying Ying Leung², ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Singapore, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, Singapore, ³Duke-NUS Medical School, Singapore, Singapore, Singapore
Background/Purpose: Fatigue is a cardinal symptom of axial spondyloarthritis (axSpA) that poses management challenges. Data on fatigue amongst Asian patients with axSpA is limited. Ethnicity…
Abstract Number: 1365 • ACR Convergence 2020
Machine Learning-based Berlin Scoring of Magnetic Resonance Images of the Spine in Patients with Ankylosing Spondylitis: Analysis of Data from a Phase 3 Trial with Secukinumab
Amir Jamaludin¹, Rhydian Windsor¹, Sarim Ather¹, Timor Kadir¹, Andrew Zisserman¹, Juergen Braun², Lianne Gensler³, Pedro Machado⁴, Mikkel Østergaard⁵, Denis Poddubnyy⁶, Thibaud Coroller⁷, Brian Porter⁷, Shephard Mpofu⁸ and Aimee Readie⁷, ¹University of Oxford, Oxford, United Kingdom, ²Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany, ³University of California San Francisco, San Francisco, CA, ⁴University College London, London, United Kingdom, ⁵Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Magnetic resonance imaging (MRI) offers a non-invasive and objective method of early diagnosis and classification, monitoring disease burden and treatment response for patients (pts)…
Abstract Number: 1871 • ACR Convergence 2020
Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Roberta Ramonda⁴, Sofia Exarchou⁵, Marleen van de Sande⁶, Floris van Gaalen⁷ and Désirée van der Heijde⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University of Padova, Padova, Italy, ⁵Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The aim of this study was to compare work-productivity and activity impairment outcomes after two-year follow-up between chronic back pain (CBP) patients with and…
Abstract Number: 1897 • ACR Convergence 2020
Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis: Data from the National Inpatient Sample 2001-2014
Anish Paudel¹, Rashmi Dhital², Dilli Poudel³, Anthony Donato¹ and Paras Karmacharya⁴, ¹Reading Hospital and Medical Center, West Reading, PA, ²Reading Hospital and Medical Center, West Reading, ³University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester MN, ROCHESTER, MN
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the spine, leading to syndesmophyte formation, ankylosis, and osteoporosis. These factors have been associated…
Abstract Number: 0156 • ACR Convergence 2020
The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis
Wojciech Tański¹, Mariusz Chabowski², Natalia Świątoniowska-Lonc³ and Beata Jankowska-Polańska³, ¹4th Military Teaching Hospital, Wrocław, Poland, ²4th Military Teaching Hospital, Wroclaw Medical University, Wrocław, Poland, ³Wroclaw Medical University, Wrocław, Poland
Background/Purpose: Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease involving the axial skeleton, entheses and peripheral joints, and may occur together with extra-articular manifestations, such…
Abstract Number: 0877 • ACR Convergence 2020
Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib
Uta Kiltz¹, Joachim Sieper², Atul Deodhar³, Patrick Zueger⁴, In-Ho Song⁴, Naijun Chen⁴ and Désirée van der Heijde⁵, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴AbbVie Inc., North Chicago, IL, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Upadacitinib (UPA) has been shown to be effective and well tolerated in patients with active ankylosing spondylitis (AS) [1]. However, improvements in global functioning…
Abstract Number: 1316 • ACR Convergence 2020
Patient Perceptions of Fibromyalgia Symptoms and the Overlap with Axial Spondyloarthritis
Kelly Gavigan¹, William Nowell², Regan Reynolds¹, Laura Stradford¹, Jeffrey R Curtis³ and Alexis Ogdie⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, New York City, NY, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: In clinical practice, it is often challenging to distinguish fibromyalgia syndrome (FMS) from axial spondyloarthritis (axSpA), which includes ankylosing spondylitis and non-radiographic axSpA. Early stages…
Abstract Number: 1366 • ACR Convergence 2020
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation
Juergen Braun¹, Ricardo Blanco², Helena Marzo-Ortega³, Lianne Gensler⁴, Filip Van den Bosch⁵, Hideto Kameda⁶, Denis Poddubnyy⁷, Marleen van de Sande⁸, Anna Wiksten⁹, Brian Porter¹⁰, Santiago Moreno⁹, Abhijit Shete⁹, Hanno Richards⁹, Sibylle Haemmerle⁹ and Atul Deodhar¹¹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁴University of California San Francisco, San Francisco, CA, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Toho University, Tokyo, Japan, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Oregon Health & Science University, Portland, OR
Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis…
Abstract Number: 1872 • ACR Convergence 2020
Relative Associations of Sociodemographic, Clinical and HLA-B Alleles with Enthesitis and Peripheral Arthritis in Patients with Ankylosing Spondylitis
Benjamin Naovarat¹, Lianne Gensler², Michael Ward³, Mark Hwang⁴, Matthew Brown⁵, Amirali Tahanan⁶, Mohammad Rahbar⁶, Mariko Ishimori⁷, Michael Weisman⁸ and John Reveille⁹, ¹The University of Texas McGovern Medical School, Houston, TX, ²University of California San Francisco, San Francisco, CA, ³National Institutes of Health, Bethesda, MD, ⁴McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁵Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁶McGovern Medical School at UTHealth, Houston, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: Previous studies from Latin America have shown an association with peripheral arthritis in patients with spondyloarthritis with HLA-B*15 (as opposed to HLA-B27). We aimed…
Abstract Number: 1898 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
Loïc Choquette Sauvageau¹, Denis Choquette², Louis Bessette³, Isabelle Ferdinand¹, Boulos Haraoui⁴, Frédéric Massicotte¹, Jean-Pierre Pelletier², Jean-Pierre Raynauld², Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Édith Villeneuve¹ and Louis Coupal¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Institut de Rhumatologie de Montréal, Montreal, Canada, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing.…
Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Johan Dalén¹, Karin Luttropp¹, Tor Olofsson², Christopher Black³ and Amy Puenpatom⁴, ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ³Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
Abstract Number: 0885 • ACR Convergence 2020
Impact of HLA-B27 Status on Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Secukinumab
Atul Deodhar¹, Philip Mease², Denis Poddubnyy³, Vibeke Strand⁴, Paula Machado⁵, Abhijit Shete⁶, Xiangyi Meng⁵ and Marina Magrey⁷, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is strongly associated with the genetic marker HLA-B27. In patients with AS, negative HLA-B27 status is a predictor of worse response…
Abstract Number: 1318 • ACR Convergence 2020
Catastrophizing in Patients with Axial Spondyloarthritis and Psoriatic Arthritis
Baptiste Coste¹, Charlotte Traverson¹, Elisabeth Filhol¹, Soraya Benamar¹, Jacques Morel², Sabine Laurent-Chabalier³, Bernard Combe⁴, Claire Daien², Cédric Lukas⁵, Charlotte Hua¹ and Cecile Gaujoux-Viala⁶, ¹Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, Nimes, France, ²Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ³Department of Biostatistics, Clinical Epidemiology, Public Health and innovation in Methodology, CHU Nîmes, University of Montpellier-Nîmes, France, Nimes, France, ⁴University of Montpellier, Montpellier, France, ⁵CHU Montpellier and University of Montpellier, Montpellier, France, ⁶Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France
Background/Purpose: Catastrophizing is a negative cognitivo-affective response to an anxiety-provoking stimulus, especially to pain. Catastrophism plays a role in maintaining chronic pain and is associated…
Abstract Number: 1411 • ACR Convergence 2020
CD8+ T Cell Subsets and Immune Checkpoint Profiles in Ankylosing Spondylitis Implicate Dysregulation of Cytotoxic T Lymphocytes (CTL)
Michael Tang¹, Zoya Qaiyum², Melissa Lim¹ and Robert Inman², ¹UNIVERSITY HEALTH NETWORK, TORONTO, Canada, ²University Health Network, Toronto, ON, Canada
Background/Purpose: Ankylosing Spondylitis (AS) is characterized by chronic inflammation which underlies the pain and precedes spinal ankylosis. The strongest genetic association with AS is the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.